The role of systemic immune-inflammation index in predicting pathological complete response of breast cancer after neoadjuvant therapy and the establishment of related predictive model.

OBJECTIVE

To investigate the role of systemic immune-inflammation index (SII) in complete pathological response (pCR) of breast cancer patients after neoadjuvant chemotherapy, and to establish and validate a nomogram for predicting pCR.

METHODS

Breast cancer patients were selected from the First Affiliated Hospital of Xi'an Jiaotong University from January 2020 to December 2023. The optimal cut-off value of SII was calculated via ROC curve. The correlation between SII and clinicopathological characteristics was analyzed by Chi-square test. Logistic regression analysis was performed to evaluate the factors that might affect pCR. Based on the results of Logistic regression analysis, a nomogram for predicting pCR was established and validated.

RESULTS

A total of 112 breast cancer patients were included in this study. 33.04% of the patients achieved pCR after neoadjuvant therapy. Chi-square test showed that SII was significantly correlated with pCR (P=0.001). Logistic regression analysis suggested that Ki-67 (P=0.039), therapy cycle (P<0.001), CEA (P=0.025) and SII (P=0.019) were independent predictors of pCR after neoadjuvant chemotherapy. A nomogram based on Ki-67, therapy cycle, CEA and SII showed a good predictive ability.

CONCLUSION

Ki-67, therapy cycle, CEA and SII were independent predictors of pCR of breast cancer after neoadjuvant chemotherapy. The nomogram based on the above positive factors showed a good predictive ability.